Australian breast cancer drug use mapped in massive data review
NCT ID NCT06624020
First seen Jun 06, 2026 · Last updated Jun 13, 2026 · Updated 2 times
Summary
This study looked at medical records from 1128 Australian patients to see how doctors prescribe CDK4/6 inhibitors (like palbociclib) for advanced or metastatic breast cancer. Researchers examined patient ages, other health conditions, and which combinations of medicines were used. No new treatments were given; the goal was simply to understand real-world prescribing patterns.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Australia
Sydney, New South Wales, 2000, Australia
Conditions
Explore the condition pages connected to this study.